Clindesse Shortage: What Providers and Prescribers Need to Know in 2026

As of 2026, Clindesse (clindamycin phosphate 2% vaginal cream) is not on the FDA's formal Drug Shortage Database. Yet clinicians across the country are receiving callbacks from patients and pharmacy teams unable to locate it. This article provides a clinical framework for managing Clindesse availability challenges — including when to substitute, what to prescribe, and how to counsel patients effectively.

Understanding Why Clindesse Is Intermittently Unavailable

Clindesse presents a structural availability challenge that differs from most common prescription medications:

No FDA-approved generic: Unlike clindamycin phosphate vaginal cream USP (Cleocin and generics), Clindesse's unique single-dose formulation has no approved AB-rated generic. Pharmacies cannot automatically substitute.

Single manufacturer: Padagis manufactures Clindesse at a single facility in Yeruham, Israel. Supply chain fragility is inherent.

Formulary and coverage variation: Many commercial plans and most Medicare Part D plans do not cover Clindesse, creating a cost barrier that reduces effective demand while complicating pharmacy inventory forecasting.

Clinical Summary: Clindesse Pharmacology

Clindesse is a lincosamide antibiotic indicated for the treatment of bacterial vaginosis in non-pregnant women. The mechanism of action involves binding to the 50S ribosomal subunit, inhibiting bacterial protein synthesis. Clindamycin phosphate is inactive in vitro; in vivo hydrolysis converts it to bacteriostatic clindamycin. It is active against anaerobes including Bacteroides spp., Mobiluncus spp., and Peptostreptococcus spp. — the primary pathogens in BV.

Systemic absorption following a single intravaginal dose is minimal (peak serum concentration approximately 20 hours post-dosing), significantly lower than oral or IV clindamycin. However, enough systemic absorption can occur to warrant consideration of C. difficile risk and neuromuscular effects in susceptible patients.

Evidence-Based Substitution Options

The 2021 CDC STI Treatment Guidelines recommend the following as first-line and alternative BV treatments, all of which are viable substitutes for Clindesse:

First-Line Alternatives (CDC Recommended)

Metronidazole 500 mg PO BID × 7 days: First-line, highly effective, generic available. Avoid in patients with documented metronidazole allergy or intolerance. Advise against alcohol use during treatment.

Metronidazole 0.75% vaginal gel, 5 g intravaginally QD × 5 days: First-line topical alternative. Generic available. Does not weaken latex condoms. Lower systemic absorption than oral formulation.

Clindamycin vaginal cream 2% (Cleocin/generic), 5 g QHS × 7 days: First-line in patients with metronidazole allergy/intolerance. Generic available. FDA-approved for non-pregnant and pregnant patients (2nd/3rd trimester). Weakens latex products for 5 days.

Alternative (Non-First-Line) Regimens

Tinidazole 2 g PO QD × 2 days or 1 g PO QD × 5 days: Alternative regimen. Generic available. Avoid in pregnancy. May have fewer GI side effects than metronidazole for some patients.

Secnidazole 2 g oral granules × single dose (Solosec): Alternative regimen. Single-dose convenience. Higher cost; limited long-term outcome data vs. first-line agents.

Xaciato (clindamycin 2% vaginal gel) single intravaginal dose: Newer single-dose clindamycin gel. Phase 3 trial showed 86% clinical cure rate at day 21 vs. placebo. Nearest equivalent to Clindesse's convenience. Brand-only; cost/coverage variable.

Special Populations: Key Considerations

Pregnancy: Clindesse is NOT recommended in pregnancy (insufficient safety data). Use Cleocin vaginal cream (generic) or oral metronidazole for pregnant patients.

Metronidazole allergy/intolerance: Cleocin vaginal cream (generic clindamycin vaginal cream) is the first-line alternative. Available at most pharmacies with a generic.

C. difficile history: Clindesse and all clindamycin-containing preparations are contraindicated in patients with a history of C. difficile-associated diarrhea. Use metronidazole or secnidazole instead.

Latex condom/diaphragm users: Counsel patients that Clindesse's mineral oil base weakens latex for 5 days. If barrier contraception reliability is a priority, oral metronidazole or metronidazole vaginal gel are preferred.

How to Help Your Patients Find Clindesse When It's Available

When Clindesse is the appropriate choice and you want to help your patient find it, medfinder for providers offers a tool to help patients locate in-stock pharmacies without time-consuming staff callbacks. medfinder calls pharmacies on the patient's behalf and texts them results, reducing the number of prescription-related callbacks your office receives.

Patient Counseling Points

Do not rely on condoms or diaphragms for 5 days after Clindesse (oil base weakens latex)

Clindesse may increase risk of vaginal yeast overgrowth (candidiasis reported in 14% of patients in trials)

Padagis savings program (clindesse.com, 1-844-492-9820): commercially insured patients may pay as little as $25

GoodRx can reduce cash price from ~$203 to approximately $109 at many pharmacies

See also: How to Help Your Patients Find Clindesse in Stock: A Provider's Guide for a workflow-focused companion article.